StockData
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX) income statement

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3019% above fair value
$0.77−0.05 (-5.87%)

Close on Nov 20, 2026Market cap $195.22MP/E –Yield –

Lineage Cell Therapeutics, Inc. financial ratios

See a number that looks wrong?